GleamWall
中文EN

PMN ProMIS Neurosciences Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1374339 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY62.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-152.3%
ROA-113.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.4%
Debt / equity0.00x
Current ratio8.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio7.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$33.38M$10.64M
SG&A expense$6.79M$6.19M
Operating income-$40.17M-$16.83M
Income tax—$0
Net income-$39.72M$2.78M
EPS (basic)-22.612.68
EPS (diluted)-22.612.63
Weighted avg. shares (diluted)1.76M1.06M
Balance sheet
Cash & equivalents$6.12M$13.29M
Short-term investments$33,753$33,051
Current assets$9.18M$18.91M
Total assets$9.18M$18.91M
Current liabilities$10.41M$2.22M
Total liabilities$10.44M$2.42M
Shareholders' equity-$1.26M$16.49M
Shares outstanding2.15M1.31M
Cash flow statement
Operating cash flow-$28.12M-$27.18M
Investing cash flow-$702-$693
Financing cash flow$20.94M$27.88M
Stock-based compensation$857,628$825,808

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.